Louisiana State University

LSU Digital Commons
Faculty Publications

Department of Biological Sciences

12-1-2016

PEG3 binds to H19-ICR as a transcriptional repressor
An Ye
Louisiana State University

Hongzhi He
Louisiana State University

Joomyeong Kim
Louisiana State University

Follow this and additional works at: https://digitalcommons.lsu.edu/biosci_pubs

Recommended Citation
Ye, A., He, H., & Kim, J. (2016). PEG3 binds to H19-ICR as a transcriptional repressor. Epigenetics, 11 (12),
889-900. https://doi.org/10.1080/15592294.2016.1255385

This Article is brought to you for free and open access by the Department of Biological Sciences at LSU Digital
Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital
Commons. For more information, please contact ir@lsu.edu.

Epigenetics

ISSN: 1559-2294 (Print) 1559-2308 (Online) Journal homepage: https://www.tandfonline.com/loi/kepi20

PEG3 binds to H19-ICR as a transcriptional
repressor
An Ye, Hongzhi He & Joomyeong Kim
To cite this article: An Ye, Hongzhi He & Joomyeong Kim (2016) PEG3 binds to H19-ICR as a
transcriptional repressor, Epigenetics, 11:12, 889-900, DOI: 10.1080/15592294.2016.1255385
To link to this article: https://doi.org/10.1080/15592294.2016.1255385

View supplementary material

Published online: 19 Oct 2017.

Submit your article to this journal

Article views: 782

View related articles

View Crossmark data

Citing articles: 7 View citing articles

Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=kepi20

EPIGENETICS
2016, VOL. 11, NO. 12, 889–900
http://dx.doi.org/10.1080/15592294.2016.1255385

RESEARCH PAPER

PEG3 binds to H19-ICR as a transcriptional repressor
An Ye, Hongzhi He, and Joomyeong Kim
Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, USA

ABSTRACT

Paternally expressed gene 3 (Peg3) encodes a DNA-binding protein with 12 C2H2 zinc ﬁnger motifs. In the
current study, we performed ChIP-seq using mouse embryonic ﬁbroblast (MEF) cells. This experiment
identiﬁed a set of 16 PEG3 genomic targets, the majority of which overlapped with the promoter regions
of genes with oocyte expression. These potential downstream genes were upregulated in MEF cells
lacking PEG3 protein, suggesting a potential repressor role for PEG3. Our study also identiﬁed the
imprinting control region (ICR) of H19 as a genomic target. According to the results, PEG3 binds to a
speciﬁc sequence motif located between the 3rd and 4th CTCF binding sites of the H19-ICR. PEG3 also
binds to the active maternal allele of the H19-ICR. The expression levels of H19 were upregulated in MEF
cells lacking PEG3, and this upregulation was mainly derived from the maternal allele. This suggests that
PEG3 may function as a transcriptional repressor for the maternal allele of H19. Overall, the current study
uncovers a potential functional relationship between Peg3 and H19, and also conﬁrms PEG3 as a
transcriptional repressor for the identiﬁed downstream genes.
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Introduction
Genomic imprinting is an epigenetic process by which one
allele of autosomal genes is repressed based on their parental origin.1 At present, less than 200 genes have been identiﬁed as imprinted genes, making up about 1% of the
mammalian gene catalog.2 Imprinted genes are usually clustered in speciﬁc chromosomal regions, and these imprinted
domains are regulated by cis regulatory elements, such as
imprinting control regions (ICRs).3,4 Imprinted genes
encode either proteins or noncoding RNA (ncRNA), the
majority of which have been shown to play critical roles in
controlling embryonic growth and development.5,6 Some
imprinted genes are also known to encode DNA-binding
proteins, such as Zac1 and Peg3.7,8 The DNA-binding protein encoded by Zac1 binds to the 30 enhancer of H19 as a
transcriptional activator, suggesting a functional connection
between the 2 imprinted genes, paternally expressed Zac1
and maternally expressed H19.8 Detailed surveys further
revealed that many imprinted genes behave coordinately in
response to environmental and developmental cues.8 Thus,
the similar expression responses shared among individual
imprinted genes have been a basis for the imprinting network model, in which imprinted genes are connected to
each other and co-regulated to produce common biological
outcomes.8
Paternally expressed gene 3 (Peg3) is an imprinted gene that
encodes a DNA-binding protein.7 Peg3 is also a member of an
evolutionarily conserved imprinted domain located in human

chromosome 19q13.4/proximal mouse chromosome 7.9,10 This
domain is located in the middle of C2H2 Kruppel-type zinc ﬁnger gene families.10 In fact, Peg3 itself is predicted to encode a
protein with 12 C2H2 Kruppel-type zinc ﬁngers.9,10 Recent
studies conﬁrmed that PEG3 indeed binds to a large number of
genomic targets as a DNA-binding protein.7 According to the
results, PEG3 functions as a transcriptional repressor for these
downstream genes.7 In particular, PEG3 binds to its adjacent
imprinted gene, maternally expressed Zim1. Detailed analyses
indicated that PEG3 functions as a transcriptional repressor for
Zim1, possibly through H3K9me3-mediated mechanisms.11
This possibility has been further supported by the observation
that many placenta-speciﬁc gene families associated with
H3K9me3 modiﬁcation are de-repressed in mutant embryos
lacking PEG3.12 Although premature at the moment, a series of
these recent studies suggested that PEG3 was a transcriptional
repressor for its downstream genes through H3K9me3-mediated mechanisms.11,12
As an ongoing effort, in the current study we performed a
new series of ChIP-seq experiments using mouse embryonic
ﬁbroblast (MEF) cells. This series of analyses identiﬁed a set of
16 potential downstream genes, and the majority of these genes
appear to be expressed in oocytes. Interestingly, one particular
target happens to be located within the imprinting control
region (ICR) of H19. Detailed analyses conﬁrmed the binding
of PEG3 to the H19-ICR; expression and in vitro analyses further suggest that PEG3 may function as a transcriptional
repressor for the maternal allele of the H19-ICR.
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Results
Identiﬁcation of the downstream genes of Peg3
in MEF cells
We used a different but improved approach in our PEG3 ChIPseq experiments compared to the previous study.7 First, we
used chromatin isolated from homogenous populations of MEF
cells. Second, we used a mutant model targeting the Peg3 locus
as a negative control.12 In this knockout (KO) model, transcription of Peg3 was truncated by 2 poly(A) signals inserted into
intron 5 as part of an expression cassette; thus, the PEG3 protein is depleted in these cells (Fig. 1A).11,12 We ﬁrst derived a
set of MEF cells, wild type (WT) and KO, from 14.5-days post
coitum (dpc) embryos that had been prepared through timed
mating of male heterozygotes for the KO allele and female littermates. Chromatin prepared from WT and KO MEF cells
was individually immunoprecipitated with polyclonal antiPEG3 antibody.11 Immunoprecipitated DNA, along with the 2
input DNA, was used for library construction and subsequent
sequencing, resulting in 30 to 40 millions reads per sample.
These four sets of raw sequence reads have been processed for
predicting the potential targets (peaks) of PEG3. This series of
bioinformatics processes, described in Material and Methods,
derived 2 sets of target regions: one set (56 peaks) from WT
and another set (36 peaks) from KO (Supplemental material 12). The target regions predicted only from WT, but not from
KO, have been further considered as potential target regions
for PEG3 (41 peaks). Detailed inspection of these 41 target
regions indicated that 31 targets are derived either from the 50
enhancer, promoter, or 1st intron of 16 individual genes. The
remaining 10 targets are derived from the intergenic regions

without any obvious gene association. For this study, we further
consider a set of 16 genes as potential downstream genes of
PEG3 (Table 1). Initial inspection of this set of genes provided
the following observations. First, the majority of these genes
(13 out of 16) tend to be expressed in mature oocytes, where
Peg3 is repressed by DNA methylation. The expression patterns
of potential downstream targets were surveyed through UCSC
genome browser (Microarray expression data; http://genome.
ucsc.edu/cgi-bin/hgGateway). Second, several genes are closely
associated with various cancers, in which Peg3 is also known to
be repressed by DNA methylation.13,14 These include Il1r1,
Tnik, Pdk2, Rara, Tob2, and Mta3. The expression proﬁles
observed among the downstream genes are inversely correlated
with those of Peg3. This may be an indication that Peg3 is a
potential repressor for the identiﬁed downstream genes. Third,
one particular target is localized within the imprinting control
region of H19, shown as a representative peak in Fig. 1B. This
peak is localized between the 3rd and 4th CTCF binding sites of
the H19-ICR. The potential binding and subsequent connection of PEG3 to the H19-ICR is very signiﬁcant given the functional roles played by these 2 imprinted genes; thus, this
possibility has been further analyzed in the latter half of the
current study. Overall, this series of ChIP-seq experiments
identiﬁed a set of 16 genes that may be regulated by Peg3 in
MEF cells.
Expression level of downstream genes in MEF cells and
neonatal brains
The identiﬁed Peg3 downstream genes were further analyzed as
follows. The expression levels of these genes were compared

Figure 1. PEG3 ChIP-seq using WT and KO MEF cells. (A) Schematic representation of the genomic structure of the paternally expressed Peg3. In the mutant allele, a 7.1kb cassette containing a promoterless b-galactosidase (b-Gal) and human b-actin promoter-driven neomycin resistant gene (NeoR) has been inserted between exon 5
and 6 of Peg3. The inserted cassette is ﬂanked by 2 FRT sites (open ovals), thus can be removed through FLP-mediated recombination. (B) CTCF-binding proﬁle and PEG3
ChIP-seq proﬁle on the H19 locus. The CTCF-binding proﬁles were derived from MEF cells, brain and liver tissues (upper). PEG3 ChIP-seq proﬁles were derived from WT
and KO MEF cells (lower).
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Table 1. Downstream genes of PEG3 in MEF cells (mm9).
Downstream Genes
Il1r1
Prpf18
Prdm11
Tnik
H19
Znrf1
Aplp2
Slc35f2
Pdk2
Msl1
Rara
Tob2
Dazap2
Ddah2
Mta3
Msl3

Chr

Start

End

Log(P-value)

Position

Expression in Oocytes

chr1
chr2
chr2
chr3
chr7
chr8
chr9
chr9
chr11
chr11
chr11
chr15
chr15
chr17
chr17
chrX

40332678
4541553
92886522
28161777
149766258
114060140
30983874
53677080
94902125
98657458
98797334
81688742
100446383
35196409
84105659
165112380

40332891
4541865
92886836
28162142
149766677
114060288
30984043
53677370
94902816
98658323
98797535
81689010
100446839
35196881
84105885
165112547

19.98059
26.30039
33.32309
26.96248
22.19105
23.08086
18.07835
13.17297
19.21628
26.64127
28.34715
12.14457
55.06908
51.20489
13.16938
17.96076

1st intron
50 enhancer
50 enhancer
50 enhancer
50 enhancer
promoter
intron
30 enhancer
promoter
promoter
50 enhancer
promoter
1st intron
1st intron
1st intron
promoter

CCC
CC
C
C
C
C
C
CC
no
CC
no
CCC
CC
no
CCC
CCC

between the WT and KO cells lacking the protein PEG3 by
qRT-PCR analyses (Fig. 2). This series of expression analyses
used 2 sets of total RNA: the ﬁrst set was from MEF cells
and the second set from neonatal brains. According to the
results from MEF cells, the majority of tested genes were
upregulated in KO cells, except Il1r1 and Slc35f2. The
observed upregulations were statistically signiﬁcant: 10 genes
showed 1.3 to 2.3-fold upregulation while 4 genes displayed
more than 3-fold upregulation. Among all the tested genes,
H19 displayed the most dramatic upregulation (6-fold) followed by Pdk2 (4.3-fold), Msl1 (3.6-fold), and Msl3 (3.2fold). On the other hand, results from neonatal brains displayed overall less dramatic changes. Among 16 tested genes,
6 genes displayed statistically signiﬁcant changes: 5 genes
showed upregulation and 1 downregulation. In particular,
the expression level change of H19 (1.4-fold) was much
smaller than the 6-fold upregulation observed in MEF cells.
In contrast, the 3 following genes showed more than 2-fold
upregulation: Tnik (2.3-fold), Il1r1 (2.9-fold), and Mta3 (2.7fold). It is prudent to note that the expression levels of the

majority of the genes observed from neonatal brains were
much lower than those observed from MEF cells. For
instance, the average threshold cycle (Ct) values of the tested
genes were around 25 for MEF cells and 30 for neonatal
brains, while the Ct values for an internal control Gapdh
were around 19 to 20 in both cases. This is particularly the
case for 2 genes, Msl1 and Msl3, the expression levels of
which were almost undetectable in the neonatal brains.
Thus, the values for these 2 genes are missing in the neonatal
brain set. A similar series of qRT-PCR analyses were also
performed using 13-dpc embryos, and the results also indicated that less dramatic changes were observed from
embryos of this stage (Supplementary Fig. 1). Overall, this
series of analyses demonstrated that the expression levels of
the majority of identiﬁed downstream genes of Peg3 were
upregulated in cells lacking PEG3, suggesting that PEG3may
function as a transcriptional repressor for the identiﬁed
downstream genes. The observed upregulation was also
much more pronounced in MEF cells than in neonatal brains
and embryos. We repeated a similar series of expression

Figure 2. Expression level changes of the identiﬁed downstream genes of Peg3. A series of qRT-PCR analyses were performed to measure the expression level changes of
the potential downstream genes of Peg3 using the total RNA isolated from the MEF cells (A) and the neonatal brains (B). For each gene, the expression levels were ﬁrst
normalized with an internal control, and the normalized values were subsequently compared between KO and WT samples. The graph summarizes the relative expression
levels of each gene with standard deviation, the statistical signiﬁcance of which was further tested with Mann Whitney U test. This series of expression analyses were also
performed using 2 independent sets of MEFs and neonatal brains.
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analyses using another set of independent MEFs, neonatal
brains, and embryos, and the results were very similar to the
patterns described above.
H19 upregulation by PEG3 depletion
The upregulation of H19 observed in MEF cells and neonatal
brains was further characterized (Fig. 3). This upregulation
could be either a direct or indirect outcome of PEG3 depletion.
Therefore, another series of expression analyses were performed with a set of additional genes that may be associated
with the function of the H19-ICR or the transcription of H19
itself. The list of additional genes includes Igf2, Igf2r, Ctcf, and
Zac1. The transcriptional levels of Igf2 and Igf2r are closely
associated with those of H19.15 On the other hand, both Ctcf
and Zac1 are known to control the transcription levels of H19
as activators.8,16-18 This list also includes 2 unrelated genes, Yy1
and p53, as negative controls. According to the results from
MEF cells, the expression levels of 4 genes were upregulated in
KO cells: Ctcf (1.5-fold), Zac1 (2.7-fold), Igf2r (2-fold), and Igf2
(7-fold). In contrast, the 2 negative control genes, Yy1 and p53,
did not show major differences (greater than 10%) between
WT and KO cells, indicating that depletion of PEG3 did not
have a global impact on transcription in MEF cells. Interestingly, the 2 known activators for H19, Ctcf and Zac1, turned
out to be upregulated; thus, it is possible that depletion of
PEG3 caused upregulation of H19 through these 2 transcription
factors. However, given the expression level changes in these
genes, 6-fold change for H19 vs. 1.5-fold and 2.7-fold change
for Ctcf and Zac, respectively, PEG3 might regulate the expression of H19 as a trans factor. On the other hand, upregulation
of Igf2 and Igf2r was unexpected, since their transcriptional levels, at least for Igf2, are usually inversely correlated with those
of H19.19 Two independent surveys were also performed using
total RNA from neonatal brains and livers. According to the

results from the neonatal brain set (Fig. 3B), no major changes
between WT and KO were observed, except for the fact that
H19 was still upregulated. In the case of the neonatal liver set,
the expression level of H19 was also upregulated, whereas that
of Igf2 was not affected (Supplementary Fig. 3). Overall, this
series of analyses concluded that upregulation of H19 is likely
an outcome of speciﬁc changes that happen on the H19/Igf2
locus, but not of global effects that are driven by the depletion
of PEG3.
PEG3 binding to the H19-ICR
We also further characterized the potential binding of PEG3
to the H19-ICR using the following approaches. We repeated
ChIP experiments using the 2 sets of chromatin prepared
from MEF cells and neonatal brains (Fig. 4A). We ﬁrst tested
the feasibility of the ChIP experiments using the known target region phosphoglucomutase 2 like 1 (Pgm2l1), as a positive control.7 As predicted, speciﬁc enrichment was detected
at the Pgm2l1 locus in WT cells, but not in the KO cells lacking PEG3. This was also the case for the neonatal brain set,
conﬁrming the binding of PEG3 to this locus as well as the
speciﬁcity of the ChIP experiments. For the actual test on the
H19-ICR, we used 2 primer sets: the ﬁrst set targeting the
entire region of the initial peak (H19-ICR, 420 bp in length);
the second set targeting the narrow region immediately surrounding the summit of the peak (H19-Peak, 152 bp in
length). These primer sets were tested on the 2 sets of ChIP
DNA. As shown in Fig. 4A, speciﬁc enrichments were indeed
observed only from the WT sets, but not from KO sets, conﬁrming the actual binding of PEG3 to the H19-ICR. Quantitative measurement of these enrichments also supported
binding of PEG3 to the H19-ICR (Supplementary Fig. 4).
The enrichment (or binding) was much more obvious
with the second primer set, further suggesting that PEG3

Figure 3. Expression level changes of H19-related genes. A series of qRT-PCR analyses were performed to measure the expression level changes of the genes associated
with the H19-ICR or H19 transcription using the total RNA isolated from the MEF cells (A) and the neonatal brains (B). For each gene, the expression levels were ﬁrst normalized with an internal control, and the normalized values were subsequently compared between KO and WT samples. The graph summarizes the relative expression
levels of each gene with standard deviation, the statistical signiﬁcance of which was further tested with Mann Whitney U test. This series of expression analyses were also
performed using 2 independent sets of MEFs and neonatal brains.
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Figure 4. PEG3 binding to the H19-ICR. Individual ChIP experiments were performed to conﬁrm the in vivo binding of PEG to the H19-ICR using 2 sets of chromatins prepared from MEF cells and neonatal brains (A). Each set of chromatin was also derived from 2 different samples, representing WT and KO (C/-p) cells. Since Peg3 is
expressed mainly from the paternal allele, the heterozygotes with the paternal transmission are considered to be null. Three individual DNA were derived from each ChIP
experiment, and used as templates for PCR survey: Input, Negative control (Neg), and the immunoprecipitated DNA with anti-PEG3 antibody (PEG3 IP). PCR-based surveys
tested 3 individual regions: Pgm2l1 as a positive control that has been known to be bound by PEG3, H19 ICR to test the 420-bp-long peak region, and H19 Peak to test the
152-bp-long narrower peak region of the H19-ICR. (B) Allele test of PEG3 binding. Individual ChIP experiments were repeated with the chromatin isolated from the 11.5dpc F1 hybrid embryos that had been prepared through the crossing between male Spretus and female C57BL/6J (B6). A restriction enzyme digestion (AcuI) showed 2
alleles in the Input as well as the immunoprecipitated DNA, but with different ratios between the 2 alleles, which are shown underneath the gel images. (C) Imprinting
test of H19 expression. Total RNA was isolated from 2 sets of the F1 hybrid samples and 2 sets of hybrid MEF cell samples that had been prepared through the crossing
between male B6 and female PWD/PhJ. A restriction enzyme digestion (BclI) showed the 2 parental alleles (lane 1–2), and also the maternal-speciﬁc expression in neonatal brains (lane 3–4) and in MEF cells (lane 5–6).

may bind to cis-regulatory motifs located within this 152-bplong genomic interval. As shown for the H19-ICR, an independent ChIP experiment also conﬁrmed the binding of
PEG3 to half of the potential targets identiﬁed through
ChIP-seq (Supplementary Figs. 6 and 7).
Since H19 is imprinted, we also tested the allele speciﬁcity of
PEG3 binding to the H19-ICR. For this test, we prepared
another set of chromatin isolated from 11-dpc F1 hybrid
embryos that had been prepared through the interspeciﬁc
crossing between male Spretus and female C57BL/6J (B6). As
shown in Fig. 4B, restriction enzyme digestion of the input
DNA showed 2 parental alleles, although the Spretus allele was
over-represented relative to the B6 allele due to the heteroduplex formation between Spretus and B6 strands during PCR
and subsequent resistance to the restriction enzyme digestion
(1 to 0.35). Nevertheless, digestion of the DNA immunoprecipitated with anti-PEG3 antibody displayed much higher levels
of the B6 allele (1 to 2.34), suggesting that PEG3 most likely
binds to the maternal allele of the H19-ICR. This further
implies that PEG3 may be functionally involved with the
maternal allele of the H19-ICR. To further test this possibility,
we performed another imprinting test with total RNA isolated
from MEF cells and neonatal brains of F1 hybrids that had
been prepared through the interspeciﬁc crossing between male

B6 and female PWD/PhJ. This set of total RNA was ﬁrst
reverse-transcribed and later ampliﬁed with a primer set
encompassing a sequence polymorphism that can be recognized by the restriction enzyme BclI (Fig. 4C). The restriction
enzyme digestion showed that H19 was still expressed mainly
from the maternal allele in both cells and neonatal brain tissues.
This was also the case for the imprinting status of Igf2, still
showing paternal expression (Supplementary Fig. 2). This indicated that depletion of PEG3 did not cause any change in the
imprinting status of H19, suggesting no impact on the
imprinted paternal allele. Instead, depletion of PEG3 may have
an impact on the active maternal allele of the H19-ICR, resulting in the upregulation of H19 in MEF cells, neonatal brains,
and livers. Taken together, this series of analyses suggests that
PEG3 most likely binds to the maternal allele of the H19-ICR
as a repressor to control the transcriptional levels of H19.
PEG3 binding site within the H19-ICR
The predicted binding sites of PEG3 localized within the
H19-ICR were further characterized with a series of gel shift
assays (Figs. 5 and 6). This series of gel shift assays were
performed with several sets of oligonucleotide duplexes.
First, a 39-bp-long duplex from the Pgm2l1 locus was used
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Figure 5. Electromobility shift assay for the DNA-binding sites of PEG3 within the H19-ICR. (A) The 152-bp-long region within the H19-ICR was divided into 3 individual
50-bp-long regions, and used as oligonucleotide duplexes, H19–1, H19–2, H19–3. The 32-bp-long duplex from Pgm2l1 was used as a P32-radiolabeled probe. The 50-bplong region surrounding the 3rd CTCF site of the H19-ICR was also included as a control. Excessive amount (200X) of unlabeled Pgm2l1, H19–1, H19–2, H19–3 and CTCF
were competed against the radiolabeled H19–1 probe. The H19–1 duplex competed well against the labeled Pgm2l1 probe, indicating that the DNA-binding site for
PEG3 is localized within the covered region by H19–1. (B) A reciprocal set of competition assays were also performed using H19–1 as a radiolabeled probe (left). A separate super shift assay was also performed to conﬁrm that the complex binding to H19–1 is indeed the protein PEG3 (right). (C) Shown are the sequences of the duplexes
used for the EMSA.

as a positive control, since this locus has been proven to be
a target of PEG3.7 Second, the 152-bp-long H19 Peak
region, the smallest target of PEG3 within the H19-ICR
(Fig. 4A), was further divided into 3 50-bp-long individual
regions, which were subsequently used as a set of 3 testing
duplexes, H19–1, ¡2, and ¡3. Finally, the 50-bp-long
region surrounding the 3rd CTCF site of the H19-ICR was
used as a negative control. According to the results, the
P32-labeled Pgm2l1 probe was bound by a protein complex
known contain PEG3.7 Among the tested duplexes, H19–1
was shown to compete well against the Pgm2l1 probe,
whereas the other 2 duplexes, H19–2 and H19–3, and also
the CTCF duplex, did not compete at all. This was further
conﬁrmed through a reciprocal set of gel shift assays, in
which the H19–1 duplex was used as a P32-labeled probe
(Fig. 5B). Consistent with the initial result, the Pgm2l1
duplex was the only duplex that competed well against the
H19–1 probe. As expected, the 3 remaining duplexes, H19–
2, H19–3 and CTCF, did not compete against the H19–1
probe. Also, a set of super shift assays demonstrated that
the protein complex bound by the H19–1 probe is indeed
the complex containing PEG3 (Fig. 5B). Taken together,
this series of gel shift assays conﬁrmed that the 50-bp-long
region covered by the H19–1 duplex most likely contains
the binding site for PEG3. Furthermore, this 50-bp-long
region may be the only region that is responsible for the
binding to PEG3 within the H19-ICR.
The actual binding sites of PEG3 within the H19–1 region
were further narrowed down with another set of gel shift

assays (Fig. 6). This series of analyses used 2 sets of mutant oligonucleotide duplexes. For the ﬁrst set of mutant duplexes, the
50-bp-long H19–1 region was again divided into 3 regions,
and the sequence of each region was all mutated into As:
MuL1, MuL2, and MuL3 (Fig. 6). These three mutant duplexes
were tested against the original H19–1 probe. The results indicated that the 2 duplexes, MuL1 and MuL2, did not compete
well, suggesting that the region covered by these 2 duplexes
likely contains the actual targets of PEG3. Thus, we prepared
the second set of mutant duplexes. In this set, the 14-bp-long
A stretches of each of the 2 duplexes, MuL1 and MuL2, was
further divided into 2 individual stretches of 7-bp-long As:
Mu1a, Mu1b, Mu2a, Mu2b. We performed another competition assay with these 4 mutant duplexes. The results indicated
that 2 duplexes, Mu1a and Mu2b, did not compete well against
the original H19–1 probe, suggesting that these 2 small regions
may be the most critical regions for the binding to PEG3.
Inspection of these 2 small regions revealed that the 2 contain
or overlap with a small motif that resembles part of the known
motif of PEG3, GTGG (Fig. 6B).7 It is also interesting to note
that the 450-bp region surrounding 2 CTCF sites also contains
2 potential binding sites for an orphan nuclear receptor family.20 These two sites, AB-2 and AB-3, are localized just outside
of the 2 PEG3 binding sites, thus suggesting that this 450-bp
region may be a main regulatory center attracting several transcription factors besides CTCF and PEG3 for the transcription
control of H19 and Igf2. Overall, this series of analyses identiﬁed 2 7-bp-long small regions within the H19-ICR as potential
binding sites for PEG3.
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Figure 6. Mutational analyses of the PEG3 binding site of the H19-ICR. The identiﬁed 50-bp-long H19–1 region was further analyzed with 2 sets of mutant oligonucleotide duplexes. (A) The 50-bp-long H19–1 was divided into 3 14-bp-long
regions, and the bases within each region were all mutated into As. These mutants,
MuL1, MuL2, MuL3, were competed against the original H19–1 probe (left). The
region covered by MuL1 and MuL2 was further divided into 4 individual 7-bp-long
regions, and each region was again mutated with As. These four mutants were
competed against the H19–1 probe (right). (B) The results indicated that 2 7-bplong regions, Mu1a and Mu2b, are the most critical for the binding to PEG3, which
are indicated by asterisks (top). The schematic diagram shows part of genomic
structure of the H19-ICR with the relative positions of H19–1, H19–2, H19–3, AB-2,
AB-3 and 2 CTCF sites (bottom).

PEG3 as a transcriptional repressor for H19
We further tested a potential repressor role of PEG3 in the
transcription of H19 using the following in vitro experiments
(Fig. 7). As mentioned before, in KO cells transcription of Peg3
is truncated by the inserted cassette, which is ﬂanked by 2 Flippase Recombination Target (FRT) sites. A vector construct
expressing Flippase (FLP) was transiently transfected into the
KO cells to remove the cassette, subsequently restoring transcription and translation of Peg3. Two additional sets of MEF
cells were also transfected as controls: one without vector
(Mock) and the other with green ﬂorescent protein (GFP) vector. As shown in Fig. 7B, transient expression of FLP indeed
removed the inserted cassette based on the detection of a genomic fragment without the inserted cassette. Also, RT-PCR analyses detected transcription of Peg3 only from KO cells with
FLP transfection, but not from the 2 controls, conﬁrming
restored expression of Peg3. Thus, total RNA was subsequently
isolated from the 3 sets of MEF cells for expression analyses of
H19. According to qRT-PCR results, the expression levels of
H19 in the sample with FLP transfection was indeed downregulated by 20% relative to that from the sample without vector
(Mock) (Fig. 7C). This statistically signiﬁcant downregulation
was observed from the sample with FLP, but not from the sample with GFP, thus conﬁrming that the observed downregulation is likely caused by the restored expression of Peg3. This
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further conﬁrmed the repressor role of PEG3 in the regulation
of H19 transcription.
The repressor role of PEG3 was further tested using a series
of reporter assays (Fig. 8). A promoterless luciferase vector was
used as a basic construct (Basic-Luc), modiﬁed ﬁrst by including the 610-bp-long promoter region of H19 (H19-Pro), and
later by including the 152-bp-long target region of PEG3 (WT152). Transfection of these constructs into HEK293 cells
derived the following outcomes. As expected, the promoter
region of H19 dramatically increased the reporter activity,
more than 10-fold. On the other hand, the inclusion of the
152-bp target region of PEG3 resulted in 50% reduction in the
promoter activity (Fig. 8A). This suggests that the 152-bp
region likely contains repressor elements for the transcription
driven by the H19 promoter. As a second set of assays, the
WT-152 construct were co-transfected with varying amounts
of the expression vector producing the protein PEG3.7 The
actual expression of the transfected PEG3 vector was further
conﬁrmed through Western blotting (Supplementary Fig. 5).
As shown in Fig. 8B, transfection with this expression vector at
5X dosage resulted in almost 40% reduction in reporter activity
compared to that with no expression vector. This reduction is
again consistent with the prediction that PEG3 may function as
a repressor for the transcription of H19. As a ﬁnal set of assays,
the target region of PEG3 within the WT-152 construct was
ﬁrst mutated, and later co-transfected with the expression vector of PEG3 (Fig. 8C). The results from gel shift assays demonstrated that one 7-bp-long region is critical (Mu2b in Fig. 6).
Thus, this region, along with the adjacent 7-bp-long region
(Mu2a), was similarly mutated in the WT-152 construct.
According to the results, co-transfection of WT-152 with the
5X dosage of the PEG3 expression vector resulted in 30%
reduction in the reporter activity. However, the observed reduction disappeared slightly in the Mu2a construct, but completely
in the Mu2b construct (Fig. 8C). This indicated that the second
7-bp-long region (Mu2b) is very critical for the repressor role
of PEG3. Since this small region is also known to be critical for
the binding to PEG3 (Fig. 6), these results strongly support the
idea that the repressor role of PEG3 may be mediated through
its direct binding to this particular small region of H19. Overall,
the results described above conﬁrmed that the protein PEG3
likely functions as a repressor for the transcription of H19.

Discussion
In the current study, we have identiﬁed a set of 16 genes as
potential downstream genes of Peg3 by performing ChIP-seq
experiment with MEF cells. The identiﬁed genes tend to be
expressed in oocytes and also during early embryogenesis.
Expression analyses further indicated that the majority of these
genes were upregulated in MEF cells lacking the PEG3 protein,
thus conﬁrming the repressor role for PEG3. Interestingly, the
imprinting control region of the H19/Igf2 domain turns out to
be one of the downstream targets of Peg3. The target site is speciﬁcally localized between the 3rd and 4th CTCF sites of the
H19-ICR. According to the results, PEG3 binds to the active
maternal allele of the H19-ICR, and also the depletion of PEG3
resulted in the upregulation of both H19 and Igf2 without any
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Figure 7. Expression level analyses of H19 using MEF cells with restored expression of Peg3. (A) Genomic structure of the mutant allele of Peg3 and FLP-mediated recombination scheme to restore the expression of Peg3. The inserted cassette is ﬂanked by 2 FRT sites, thus can be removed by Flippase (FLP). (B) Three pools of KO MEF cells
were individually transfected with the following constructs: no vector as a mock control (lane 1), a GFP expression vector as a negative control (lane 2), and a FLP expression vector (lane 3). The total RNA isolated from these cells were analyzed with qRT-PCR to measure the expression levels of b-actin and Peg3. The bottom panel shows
genotyping results conﬁrming FLP-mediated recombination of the mutant allele (Rev KO) and endogenous allele (WT) of Peg3. (C) The total RNA isolated from the 3 sets
of MEF cells were also used for measuring the expression levels of H19. The expression level of H19 was ﬁrst normalized with an internal control (Gapdh), and the normalized values from the 3 sets of MEFs were subsequently compared. The values from the MEF cells transfected with GFP and FLP were divided by the value from a Mock
control. Finally, these relative values were presented in the graph with standard deviation, the statistical signiﬁcance of which was further tested with Mann Whitney U
test.

changes in their imprinting status. This conﬁrms a repressor
role for PEG3 in the transcriptional regulation of H19 and Igf2.
Overall, the current study uncovers a functional connection
between the 2 imprinted genes, with the paternally expressed
Peg3 acting as a trans factor controlling the maternally
expressed H19.
The protein PEG3 appears to control a set of 16 potential
downstream genes as a DNA-binding transcription factor
(Table 1 and Supplementary Fig. 6). The results from ChIP-seq
provide the following insights regarding the function of PEG3.
First, the number of potential downstream genes identiﬁed
from MEF cells is relatively small compared to those from the
other known DNA-binding transcription factors, 16 vs. several
hundreds.21 The expression levels of PEG3 are known to be
very high in early-stage tissues and neuronal cells.9 Nevertheless, PEG3 seems to bind to a very small subset of genes in
MEF cells. This might be related to the following possibility.
PEG3 has been detected not only in the nucleus but also in the
cytoplasm, suggesting unknown cytoplasmic functions other
than DNA-binding nuclear functions.22,23 It is possible that
only a small fraction of the PEG3 protein functions as a DNAbinding protein, especially in MEF cells. As a consequence, this
very limited amount of PEG3 may be available for binding and
controlling a small subset of genes. It is, however, also possible
that some unknown technical problems involving ChIP and
next generation sequencing experiments might have caused

this small number of peaks. Second, the identiﬁed downstream
genes were shown to be all upregulated by the depletion of
PEG3 (Figs. 2 and 3). This appears to be consistent with the
observations derived from previous studies.7,11 The two known
downstream genes, Pgm2l1 and another imprinted gene, Zim1,
were also upregulated in KO cells lacking PEG3. Therefore, it is
most likely that PEG3 may also function as a repressor for the
newly identiﬁed downstream genes. Third, the identiﬁed genes
seem to share several features, such as expression in oocytes
and close association with human cancers. As described earlier,
it is interesting to note that the expression level of Peg3 is very
low in both oocytes and some cancers, especially breast and
ovarian cancers.13 This inverse correlation again supports a
repressor role of PEG3 for the identiﬁed downstream genes. In
particular, a subset of these potential downstream genes is
highly expressed and also mainly functional during oogenesis
and/or early embryogenesis. This subset includes Msl1 and
Msl3 (Table 1). The expression levels of these genes are very
low in the later-stage cells, when Peg3 is highly expressed.
Thus, one of the main functions of Peg3 might be repressing
this set of genes in those somatic cells. Although very speculative at the moment, this might be also one reason why Peg3
needs to be repressed by DNA methylation during oogenesis.
On the other hand, since human PEG3 has been regarded as a
tumor suppressor,24 the identiﬁed downstream genes with cancer connection might provide potential mechanisms by which
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Figure 8. Testing the repressor role of PEG3 through reporter assays. (A) This series of reporter assays used the following 3 constructs. The Basic-Luc construct with a promoterless luciferase reporter was modiﬁed ﬁrst by inserting the 610-bp-long promoter region of H19 (H19-Pro), and later by inserting the additional 152-bp-long target
region of PEG3 (WT-152). The reporter activity from these 3 constructs was summarized and presented as a graph on left. (B) The WT-152 construct was co-transfected
with varying amount of the expression vector producing the full-length PEG3 protein. In this series of co-transfection experiments, 10 ng of the expression vector was
considered as 1X. The luciferase activity for each sample was ﬁrst compared to that of the control sample with no expression vector, and this relative value was summarized and presented along with standard deviation on a graph. The statistical signiﬁcance of the observed change was further tested using Mann Whitney U test. (C) The
WT-152 construct was further tested after mutating the potential binding sites of PEG3. The constructs, Mu2a and Mu2b, are identical to WT-152 except that each construct has a 7-bp-long mutation on the critical region for the binding to PEG3. The exact mutation spot for each construct is same as its corresponding duplex mutant
used for gel shift assays (Fig. 6).

PEG3 may suppresses tumor formation. For instance, MTA3 is
very closely associated with breast cancer as an oncogene;25
thus, it would be interesting to further characterize a potential
connection between PEG3 and MTA3, speciﬁcally to test
whether PEG3 functions as a tumor suppressor by repressing
oncogenic MTA3. In sum, the protein PEG3 appears to be a
transcriptional repressor for a small number of genes that are
closely associated with either early developmental processes or
human cancers.
One of the unexpected outcomes from the current study
was that PEG3 bound to the ICR of the H19/Igf2 domain, speciﬁcally to the region between the 3rd and 4th CTCF binding
sites (Fig. 1B). This binding by PEG3 also appears to be speciﬁc to the maternal allele, which is unmethylated and active
(Fig. 4B). Consistent with this, PEG3 binding to DNA is
indeed methylation sensitive (Supplementary Fig. 8). The
functional outcome of this binding turned out to be repressing
the expression of H19 in MEF cells, 13-dpc embryos, and in
the brain and liver of neonates (Figs. 2 and 3, Supplementary
Fig. 1 and 3). This has been further followed up with a series
of in vitro experiments as shown in Figs. 7 and 8, further supporting a repressor role of PEG3 in the expression of H19.
The observed repressor role of PEG3 is very interesting since
this cis-regulatory region bound by PEG3 is localized in the
middle of the ICR of the H19/Igf2 domain. The ICR of H19/

Igf2 has been mainly characterized as a methylation-sensitive
insulator region, controlling the allelic expression of both H19
and Igf2. According to the expression analyses, however, the
depletion of PEG3 appears to affect mainly the expression levels of H19, but not those of Igf2: 1.5-fold upregulation of H19
vs. almost no changes in Igf2 in the brain and liver of the
Peg3-KO neonates (Fig. 2B and Supplementary Fig. 3).
Although statistically signiﬁcant, the levels of the observed
changes in H19 expression were relatively small (1.5-fold).
This is quite different from the levels of the changes observed
from MEF cells, showing 6- to 7-fold upregulation (Figs. 2
and 3). Although the dramatic upregulation in MEF cells is
still supportive of a repressor role for PEG3, this observation
needs to be interpreted with caution since these tests were performed using an in vitro system. In contrast, the much smaller
changes observed in in vivo tissues might be reﬂecting the
genuine outcome of PEG3 depletion on H19 expression, and
also the possibility much greater changes in H19 expression
might have been lethal during mice embryogenesis. It is also
relevant to point out that expression level changes observed in
mouse brains might not be as dramatic as in MEFs since those
changes are the averaged values of heterogeneous cell populations within brains. Overall, the results described above suggest that the binding of PEG3 to the maternal allele of the
ICR is most likely responsible for the transcriptional
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regulation of H19 expression. At the same time, it would be
interesting to pursue potential roles for PEG3 in the regulation
of H19 in other tissues, such as testes, where Peg3 is
highly expressed but H19 is transcriptionally repressed and
methylated.
PEG3 depletion seems to have a more complicated and
global outcome than expected, according to the results from
several series of expression analyses (Figs. 2 and 3 and
Supplementary Figs. 1–3). The expression levels of several
genes, which are not bound by PEG3, have also been shown to
be affected, including Igf2, Igf2r, Zac1, Peg10, Grb10, and Ctcf.
Among these genes, the upregulation of Igf2 is the most dramatic, with 6-fold upregulation in MEF cells, but no statistically
signiﬁcant changes observed in in vivo tissues. The upregulated
expression of Igf2 is still from the paternal allele, which is not
bound by PEG3 (Supplementary Fig. 2A). Thus, the upregulation of Igf2 might be an indirect outcome of the depletion of
PEG3. This might also be the case for several other imprinted
genes that were also affected, including Igf2r, Peg10, Zac1, and
Grb10. One plausible scenario would be that the observed
changes might be reﬂecting some changes in the proposed
imprinted gene network, which might be triggered by the
depletion of PEG3.8 In that regard, it is relevant to point out
that Peg3 is thought to be at the center of this proposed network, meaning that Peg3 has the most connections with the
other imprinted genes.8 Thus, it is reasonable to predict that
the upregulation observed from some of the imprinted genes
might be caused by potential disturbance in the imprinted gene
network. Overall, depletion of the PEG3 protein has a global
impact on the transcription of several other imprinted genes,
although it appears to controls only a few imprinted genes,
such as H19.

Materials and methods
Ethics statement
All the experiments related to mice were performed in accordance with National Institutes of Health guidelines for care and
use of animals, and also approved by the Louisiana State University Institutional Animal Care and Use Committee
(IACUC), protocol #13–061.
Derivation of MEF cells
Two litters of 14.5-dpc embryos of the C57BL/6J background
were harvested through timed mating of the male mice heterozygous for the KO allele with female wild type littermates.
The mutant allele of Peg3 used for the current study has been
previously reported and characterized in detail.12 The head
portion and the red tissues were removed from the embryos,
and the remaining portions were minced with razor blades.
These minced tissues were transferred to a 15-mL conical
tubes containing 1 mL trypsin (Invitrogen, Cat. No.
25300062). After 5 min incubation at 37 C, the cells were
harvested with centrifugation, and later resuspended in
15 mL media (Life technologies, Cat. No.10566024). Finally,
the resuspended cells were plated onto a T-75 ﬂask. The MEF
from each embryo was ﬁrst genotyped using the following

primer set: Peg3-for (50 -ATGAGTCTCGATCCCAGGTATGCC-30 ) and LoxR (50 -TGAACTGATGGCGAGCTCAGACC-30 ). Gender of each MEF was also determined using
the following primer set: mSry-F (50 -GTCCCGTGGTGAGAGGCACAAG-30 ) and mSry-R (50 -GCAGCTCTACTCCAGTCTTGCC-30 ).
ChIP and ChIP-seq analyses
Chromatin was prepared from 2 different types of samples,
MEF and neonatal brains, according to the method previously
described.7 In brief, the homogenized samples were ﬁrst crosslinked with 1% formaldehyde for 20 mins, and then lysed with
the buffer containing protease inhibitor cocktail (Millipore,
Cat. No. 539131). The released nuclei were fractionated with
sonication to derive a pool of DNA fragments sizes ranging
from 300 to 500 bp in length. The prepared chromatin was
immunoprecipitated with a commercial anti-PEG3 antibody
(Abcam, Cat. No. ab99252). The immunoprecipitated DNA
was dissolved in 100 ml of TE for PCR analyses. For ChIP-seq
analysis, 2 pools of MEF cells (WT and KO) were individually
immunoprecipitated with the anti-PEG3 antibody. The two
immunoprecipitated DNA along with the 2 corresponding
input DNA were used for constructing libraries for ChIP-seq
experiments according to the manufacturers’ protocol (Illumina FC4014003). The raw sequence reads derived from these
4 libraries, on average 35 millions read per sample, were
mapped to the mouse reference genome sequence (mm9) using
Bowtie2.26 The sam ﬁles from the mapping were ﬁrst converted
into bed ﬁles using Samtools, and later the bed ﬁles were used
for predicting peaks using MACS2.27 The ﬁnal outputs from
MACS2 describing ChIP-seq peaks are available (Supplemental
material 1–2).
Electromobility shift assay
Electromobility shift assay (EMSA) was performed using a gel
shift assay system kit (Promega Cat. No. E3053). This series of
assays also used mouse brain nuclear extract (Active Motif Cat.
No. 36053) since Peg3 is highly expressed in the brain tissue.9,10
The competition assays were performed in the following manner. Brieﬂy, the binding buffer, 2.72 mg mouse brain nuclear
extract and unlabeled competitor oligonucleotide duplexes
(1.74 pmol, 200X) were ﬁrst incubated at room temperature
10 mins. Later, 1 ml of P32-labeled duplex probe (1X) was added
and incubated at room temperature for additional 20 mins. The
reaction mixture was subsequently separated on a 5% TBE gel
(Bio-Rad Cat. No. 456–5014), and exposed to ﬁlm for 2 to 6
hat ¡80 C. For super shift assays, the initial reaction mixture
was incubated along with an antibody, either anti-PEG3 antibody or anti-YY1 antibody (Santa Cruz, Cat No. 1703X), and
later incubated with P32-labeled duplex probe.
Transfection experiments
MEF cells were transfected with the following 2 constructs,
GFP (pIRES-puro-GFP) and FLP (pIRES-puro-FLP), using the
GenJet transfection reagent (Cat. No. SL100489-MEF). Transfection efﬁciency was also monitored through GFP expression
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under a ﬂuorescence microscope at 24-hour post transfection.
The transfected cells were harvested at 72-hour post transfection for RNA and DNA isolation. The reverted allele of Peg3 by
FLP was detected through PCR with the following primer set:
Flpko-F (50 -CCCTCAGCAGAGCTGTTTCCTGCC-30 ) and
Flpko-R (50 -AAGCTACCTGGGAAATGAGTGTGG-30 ).
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RNA isolation and qRT-PCR analyses
Total RNA was isolated from either MEF or the brains of one-dayold neonates using a commercial kit (Trizol, Invitrogen). The total
RNA was then reverse-transcribed using the M-MLV kit (Invitrogen), and the subsequent cDNA was used as a template for quantitative PCR. The qRT-PCR analysis was performed with SYBR
Select Master Mix (Applied Biosystems, Life Technologies) using
the iCycler iQTM multicolor real-time detection system (Bio-Rad).
All qRT-PCR reactions were carried out for 40 cycles under standard PCR conditions with internal controls (Gapdh and b-actin).
The results derived from qRT-PCR were further analyzed using the
threshold (Ct) value. The DCt value was initially calculated by subtracting Ct value of a testing replicate of a given gene from the average Ct value of the internal control (Gapdh and b-actin). The fold
difference for each replicate was then calculated by raising the
DDCt value as a power of 2.28 The average and standard deviation
for each sample were then calculated by compiling the normalized
values. The information regarding individual primer sequences is
also available (Supplemental material 3).

Luciferase reporter assay
This series of reporter assays used the modiﬁed version of b-geo
vector29 as a control vector monitoring transfection efﬁciency, and
also the modiﬁed version of luciferase vector (Promega, PGL3) as a
basic construct testing the promoter and the PEG3-bound regions
of H19. The 610-bp-long promoter region of H19 was ﬁrst inserted
into the NotI site of the promoterless luciferase vector (Basic-Luc).
Then, this constructed vector (H19-Pro) was further modiﬁed by
inserting individually 3 152-bp-long target and its mutated versions
(WT-152, Mu2a, Mu2b) into the 50 region of the 610-bp promoter
of H19. For luciferase assay, HEK 293 cells were cultured in
DMEM plus GlutaMAX medium with 10% fetal bovine serum and
1% antibiotic-antimycotic (GibcoBRL), and plated in 12-well plates
for plasmid transfection. The cells on each well were transfected
with 4 ml lipofectamine 2000 (Invitrogen) and 1.6 mg of total
reporter construct (0.8 mg b-geo vector and 0.8 mg luciferase vector) either alone or with the expression vector containing fulllength PEG3. For a series of co-transfection experiments, an additional 10 ng of the expression vector of PEG3 was regarded as 1X,
50 ng as 5X, and so forth. Fresh complete media was added 6 hafter
transfection, and total cell lysates were harvested in 300 ml of cell
lysis buffer 48 hlater according to our previously published protocol.29 The luciferase assay was performed in triplicate, as previously
published.
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